Download PDF
Semin Liver Dis 2014; 34(01): 108-112
DOI: 10.1055/s-0034-1371084
Diagnostic Problems in Hepatology
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Case Report of Successful Treatment of Fibrosing Cholestatic Hepatitis C with Sofosbuvir and Ribavirin after Liver Transplantation

Authors

  • Brian Kim

    1   The Recanati/Miller Transplantation Institute, Mount Sinai Health System, New York, New York

  • Anshu Trivedi

    2   The Lillian and Henry M. Stratton – Hans Popper Department of Pathology, Mount Sinai Health System, New York, New York

  • Swan N. Thung

    2   The Lillian and Henry M. Stratton – Hans Popper Department of Pathology, Mount Sinai Health System, New York, New York

  • Priya Grewal

    1   The Recanati/Miller Transplantation Institute, Mount Sinai Health System, New York, New York
Further Information

Publication History

Publication Date:
29 April 2014 (online)

  Permissions and Reprints

Abstract

Fibrosing cholestatic hepatitis is an unusual complication of hepatitis C virus (HCV) recurrence after liver transplant. Fibrosing cholestatic hepatitis is marked by aggressive progression of cholestasis and fibrosis, leading to accelerated graft loss and/or death. Sofosbuvir (GS-7977) is an oral nucleotide analogue inhibitor of HCV polymerase activity. It is a second-generation, direct-acting, antiviral for the treatment of HCV infection. This case illustrates a patient with recurrent HCV with fibrosing cholestatic hepatitis, who was successfully treated with a combination of sofosbuvir and ribavirin with normalization of liver enzyme activities and resolution of HCV-related symptoms. The favorable side effect profile and the lack of drug–drug interaction with immunosuppressive medications make the combination of sofosbuvir and ribavirin a promising regimen for severe HCV recurrence.

Keywords

hepatitis C virus - fibrosing cholestatic hepatitis - cholestatic variant of hepatitis C - liver transplant - sofosbuvir - ribavirin